发布时间：2025-12-17 15:46
Post-hoc analyses of the phase III ARCADIA and OLYMPIA clinical trial programs, published in the Journal of the European Academy of Dermatology and Venereology, highlight nemolizumab’s fast onset of action and improvement of itch and sleep disturbance in patients with moderate-to-severe atopic dermatitis and prurigo nodularis1
Significant improvements in itch were observed as early as 48 hours after initial treatment and steadily increased through to Day 141
Nemolizumab is the first approved monoclonal antibody that specifically targets and inhibits the signalling of IL-31 – a neuroimmune cytokine that drives itch and other symptoms in atopic dermatitis and prurigo nodularis2-4
Nemolizumab is approved by multiple regulatory authorities around the world for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis, including in the U.S. and EU5,6




ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GAL
=*=*=*=*=*=
当前为第1/16页
下一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页